It is now widely accepted that HER3 overexpression is a mechanism of tumor-acquired resistance to different treatments, as this receptor provides compensatory signaling and, more importantly, drives persistent signaling through the PI3K/Akt pathway (1, 2). This evidence concerns the gene AKT1 and neoplasm.